504 related articles for article (PubMed ID: 28749169)
1. Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus.
Ahmadieh H; Azar S
Diabetes Technol Ther; 2017 Sep; 19(9):507-512. PubMed ID: 28749169
[TBL] [Abstract][Full Text] [Related]
2. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
Katz PM; Leiter LA
Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
[TBL] [Abstract][Full Text] [Related]
3. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Zhao Y; Xu L; Tian D; Xia P; Zheng H; Wang L; Chen L
Diabetes Obes Metab; 2018 Feb; 20(2):458-462. PubMed ID: 28846182
[TBL] [Abstract][Full Text] [Related]
4. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.
Davies MJ; Trujillo A; Vijapurkar U; Damaraju CV; Meininger G
Diabetes Obes Metab; 2015 Apr; 17(4):426-9. PubMed ID: 25600248
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
Raskin P
Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 inhibitors.
Dardi I; Kouvatsos T; Jabbour SA
Biochem Pharmacol; 2016 Feb; 101():27-39. PubMed ID: 26362302
[TBL] [Abstract][Full Text] [Related]
7. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.
Rajeev SP; Cuthbertson DJ; Wilding JP
Diabetes Obes Metab; 2016 Feb; 18(2):125-34. PubMed ID: 26403227
[TBL] [Abstract][Full Text] [Related]
8. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
Scheen AJ; Paquot N
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
[TBL] [Abstract][Full Text] [Related]
9. SGLT-2 inhibition in patients with kidney disease.
Gilbert RE
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S23-7. PubMed ID: 25554068
[TBL] [Abstract][Full Text] [Related]
10. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
Basile JN
J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
[TBL] [Abstract][Full Text] [Related]
11. Beyond Glycosuria: Exploring the intrarenal effects of SGLT₋₂ inhibition in diabetes.
Thomas MC; Jandeleit-Dahm K; Bonnet F
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S17-22. PubMed ID: 25554067
[TBL] [Abstract][Full Text] [Related]
12. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Gallo LA; Wright EM; Vallon V
Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
Misra M
J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
[TBL] [Abstract][Full Text] [Related]
14. Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors.
Mintz ML
J Fam Pract; 2016 Dec; 65(12 Suppl):. PubMed ID: 28149983
[TBL] [Abstract][Full Text] [Related]
15. Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype.
Lim LL; Tan AT; Moses K; Rajadhyaksha V; Chan SP
J Diabetes Complications; 2017 Feb; 31(2):494-503. PubMed ID: 27866701
[TBL] [Abstract][Full Text] [Related]
16. Renal glucose reabsorption inhibitors to treat diabetes.
Bailey CJ
Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects and safety of SGLT-2 inhibitors.
Halimi S; Vergès B
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S28-34. PubMed ID: 25554069
[TBL] [Abstract][Full Text] [Related]
18. Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?
Bonnet F; Scheen AJ
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S1-3. PubMed ID: 25554065
[No Abstract] [Full Text] [Related]
19. Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
Tsimihodimos V; Filippatos TD; Elisaf MS
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):399-408. PubMed ID: 27819144
[TBL] [Abstract][Full Text] [Related]
20. [Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors in CKD].
Insalaco M; Zanoli L; Rastelli S; Lentini P; Rapisarda F; Fatuzzo P; Castellino P; Granata A
G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
